Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that the Journal of Clinical Psychopharmacology has published a study ...

Researchers pinpoint the genes responsible for the final three pea traits studied by the famed citizen scientist.

Myriad Genetics, Inc. announced that a study published in the Journal of Clinical Psychopharmacology found that the GeneSight® Psychotropic Test significantly reduced psychiatric hospitalizations ...

The iconic pea plant experiments of Gregor Mendel laid the foundations for the science of genetics. Now 160 years on, an ...

Chief Scientific Officer at Myriad Genetics. “This study found lower psychiatric-related hospitalizations following use of the GeneSight test, suggesting that GeneSight may help healthcare ...

SALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that the Journal of Clinical ...

(MENAFN- GlobeNewsWire - Nasdaq) Study published in the Journal of Clinical Psychopharmacology SALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in ...

“We have achieved a breakthrough not only in terms of energy storage density and cost, but also found a new key to environmental protection.” The company’s latest product, which uses sodium ...